In 2023, Ascentage Pharma completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Ascentage Pharma has also provided a category-level breakdown for 5 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2023 | 2022 | 2021 | 2020-2019 |
|---|---|---|---|---|
Total Scope 1 | 2,081.23a | 1,329a | 7.67a | |
Total Scope 2 | ||||
Unspecified Calculation Method | 5,695.43a | 4,078.98a | 934.43a | |
Total Scope 3 | 1,309.53a | N/A | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 66.6323a | 40.4243a | 1.7511a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2023, the total operational greenhouse gas (GHG) emissions of Ascentage Pharma amounted to 7,776.66 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Ascentage Pharma increased by 43.8%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2023, the total Scope 1 emissions of Ascentage Pharma were 2,081.23 metric tons of CO₂ equivalent (tCO₂e).a
Since 2021, Ascentage Pharma's Scope 1 emissions have increased by 27,034.68%, reflecting a rising long-term trend in Scope 1 emissions over time.a
Compared to the previous year (2022), Ascentage Pharma's Scope 1 emissions increased by 56.6%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2023, Ascentage Pharma reported Scope 2 greenhouse gas (GHG) emissions of 5,695.43 tCO₂e without specifying the calculation method.a
Since 2021, Ascentage Pharma's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have increased by 509.51%, reflecting a rising long-term trend in Scope 2 emissions over time.a
Compared to the previous year (2022), Ascentage Pharma's Scope 2 emissions (Unspecified Calculation Method) rose by 39.63% in 2023, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya
In 2023, Ascentage Pharma reported its Scope 2 emissions using an unspecified methodology.a
In 2023, Ascentage Pharma reported 1,309.53 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2023 disclosure of Ascentage Pharma includes a breakdown across 5 of the 15 Scope 3 categories defined by the GHG Protocol, up from 0 in 2022, reflecting improved emissions accounting practices and greater transparency across the company's value chaina
In 2023, Ascentage Pharma reported total Scope 3 emissions of 1,309.53 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.a
In 2023, Ascentage Pharma reported emissions for 5 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This partial disclosure allows for some insight into the company's indirect impacts.
In 2023, the largest contributors to Ascentage Pharma's Scope 3 emissions were:a
In 2023, Ascentage Pharma reported Scope 1 greenhouse gas (GHG) emissions of 2,081.23 tCO₂e and total revenues of USD 31 millions. This translates into an emissions intensity of 66.63 tCO₂e per millions USD.a
In 2023, Ascentage Pharma reported a Scope 1 emissions intensity of 66.63 tCO₂e per millions USD. Compared to the peer group median of 10.66, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2023, Ascentage Pharma ranked 23 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Ascentage Pharma among the least efficient performers, with one of the highest emissions intensities in its sector.a
In 2023, Ascentage Pharma reported a total carbon footprint of 9,086.19 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 68.01% increase compared to 2022, suggesting a rise in emissions across its operations or value chain.a
The largest contributor to Ascentage Pharma's total carbon footprint was Scope 2 emissions, accounting for 62.68% of the company's total carbon footprint, followed by Scope 1 emissions at 22.91%.a